| 产品描述: | Deracoxib (SC-046) is a COX-2 inhibitor with >48-fold selectivity over COX-1. It also exhibits inhibitory activity against phosphodiesterase (Ki = 3.6 μM against human PDE4D3). |
| 靶点: |
COX2;PDE4(Cell-free assay):3.6 μM;Apoptosis;COX |
| 体内研究: |
Deracoxib (1-2 mg/kg,口服,术前 1 次,术后 2 次,共 3 天) 对犬软组织手术后疼痛控制具有显著的治疗效果。 Deracoxib (3 mg/kg,口服,每日一次,直至发现进行性疾病) 通常对犬具有良好的耐受性,并且对移行细胞癌 (TCC) 具有抗肿瘤活性。 Deracoxib (15 mg/kg,口服,每日两次,连续 26 天) 可预防小鼠 Collagen 诱发的关节炎。 |
| 细胞实验: |
Cell lines: MC4R-GLO cells Concentrations: 10 µM Incubation Time: 5 min Method: MC4R-GLO cells were plated in 12 well culture dishes in DMEM/F12 supplemented with 5% fetal bovine serum. Cells were incubated in serum-free medium over night before the experiment. Cells were then treated with the indicated concentration of α-MSH or vehicle for 5 min at 37°C in the presence or absence of 10 µM deracoxib or imperatorin. Dishes were then placed on ice and cells were scraped in 1x LDS-PAGE sample buffer with 100 mM DTT. Proteins were resolved by SDS-PAGE. |
| 参考文献: |
1. Millis DL, et al. Vet Ther. 2002, 3(4):453-64. 2. Pantel J, et al. Eur J Pharmacol. 2011, 660(1):139-47. |
| 溶解性: |
Soluble in DMSO、Ethanol |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.517 ml |
12.583 ml |
25.165 ml |
| 5 mM |
0.503 ml |
2.517 ml |
5.033 ml |
| 10 mM |
0.252 ml |
1.258 ml |
2.517 ml |
| 50 mM |
0.05 ml |
0.252 ml |
0.503 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |